Anika soars on FDA Monovisc OK
This article was originally published in Scrip
Executive Summary
Shares of Bedford, Massachusetts Anika Therapeutics soared 33.45% in after-hours trading on 25 February after the company revealed the FDA had approved Monovisc to treat pain and improve joint mobility in patients with osteoarthritis of the knee.